Tevogen Bio Holdings Inc.
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$26.3M
- Total assets
- $4.4M
- Market cap
- $43.8M
- Operating margin
- 13363.0%
- Net margin
- 13432.0%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- -$195.6K
- Operating expenses
- $26.1M
- Operating income
- -$26.1M
- Income tax
- $4.8K
- Net income
- -$26.3M
- EPS (basic)
- $-8.08
- EPS (diluted)
- $-8.08
Balance sheet
- Total assets
- $4.4M
- Current assets
- $1.5M
- Total liabilities
- $12.6M
- Current liabilities
- $7.1M
- Shareholders’ equity
- -$8.2M
Cash flow
- Operating cash flow
- -$12.3M
- Investing cash flow
- $666.2K
- Financing cash flow
- $11.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $43.8M
- EPS (diluted)
- $-8.08
- Shares outstanding
- 3.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 15, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $26.3M.
- Trading 84% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tevogen Bio Holdings Inc..
Write a review
News about Tevogen Bio Holdings Inc.
News & sentiment via Polygon.io
